agonist azelaprag with Eli Lilly’s dual GLP-1/GIP agonist tirzepatide – already approved as Zepbound for obesity treatment. The study is due to start later this year. The Richmond, California ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

People have reduced appetite, and when they do eat, they feel full sooner. Wegovy and Zepbound are approved by the U.S. Food and Drug Administration for people with obesity or those who have ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...